Compare Rent the Runway Inc (RENT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rent the Runway Inc vs TG Therapeutics Inc — how do they compare? Rent the Runway Inc trades at $1.76 (market cap $61.75M), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 132.1× Rent the Runway Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and TG Therapeutics Inc for 16 Days on average.
| RENT | TGTX | |
|---|---|---|
Market Cap | $61.75M | $8.16B |
Volume | 193,323 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $59.06 |
52-Week Low | $1.55 | $26.94 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | $228.75M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rent the Runway (RENT) trades at $1.77, up 5.36% today, with a bullish technical signal despite mixed indicators. The company reported Q2 2026 revenue growth of 20.8% year-over-year to $97.7 million, with improved gross margins, and appointed Paige Thomas as CEO in September 2026. However, it faces negative shareholder equity of -$182.5 million and a high debt-to-asset ratio of 139.62% as of 2025, though net losses have narrowed from -$212 million in 2022 to -$69.9 million in 2025.
The outlook is cautiously optimistic, with revenue growth and margin expansion offering potential upside, but significant financial leverage and ongoing legal investigations pose substantial risks. Analyst consensus is mixed, with 42% buy ratings, reflecting the balance between operational improvements and balance sheet concerns.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
